No Data
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6
Lexicon To Present Preclinical IN VIVO Efficacy Data Demonstrating Ability Of New Investigational Compound To Enhance And Maintain Semaglutide-Promoted Weight Loss, At Obesity Week 2024
Express News | Lexicon to Present Preclinical in Vivo Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
Sector Update: Health Care Stocks Rise Late Afternoon
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
Lexicon Pharmaceuticals Down Over 34%, on Pace for Largest Percent Decrease Since July 2019 -- Data Talk
No Data
No Data
